fresh take precision-guid immunotherapi
initi outperform
initi coverag biopharma outperform rate pt
base assess commerci opportun human
papillomaviru hpv -driven cancer first-in-class biolog design
select activ specif target popul endogen t-cell
first clinical-stag product emerg cue innov immuno-stat technolog
platform believ immuno-stat could repres evolutionari leap forward
rel current avail cytokin therapi checkpoint modul could
potenti deliv efficaci par person t-cell therapi without
high cost safeti concern manufactur complex would buyer
head potenti clinic proof-of-concept phase result expect
cue immuno-stat platform equip potent immuno-modulatori molecul
high-precis target system approach prevent
indiscrimin activ t-cell limit util drug
aldesleukin variant immuno-stat repres
tour-de-forc protein engin off-the-shelf product manufactur
via similar process monoclon antibodi
immuno-stat specif impart engin major histocompat
product contain well-
character hpv antigen mhc bind stimul
t-cell capabl recogn antigen word immuno-stat
activ t-cell appropri given job
immuno-stat vaccin rather design replac role
antigen present cell apc suscept interfer down-
regul tumor vaccin approach typic reli apc efficaci
wherea immuno-stat sidestep depend immuno-stat platform
modular deploy oncolog autoimmun diseas open
door partnership opportun big biopharma
current evalu phase trial patient hpv-
posit head neck cancer initi translat result support
mechan could present translat data could follow
earli evid object respons
believ develop hpv-driven cancer de-risk multipl adopt
antigen well tumor infiltr lymphocyt til therapi
deliv object respons could achiev similar-or-bett
activ conveni inject biolog
year price histori
compani develop inject
biolog treatment cancer
analyst certif import disclosur see disclosur
initi coverag biopharma outperform
rate month price target base
assess commerci potenti compani lead
product hpv-driven cancer believ
could offer signific advantag exist standard
care hpv head neck cancer well cervic
cancer see cue immuno-stat technolog innov
way dial specif cytokin therapi could
translat substanti improv safeti efficaci rel
approv r/m scchn po peak sale
us eu respect
approv r/m scchn po peak sale
us eu respect
approv advanc cervic cancer po
peak sale th us eu respect
potenti initi translat monotherapi data
potenti proof-of-concept efficaci result scchn
potenti initi dose-expans portion scchn
pembrolizumab scchn
initi combin cohort
immuno-stat framework valid addit
oncolog autoimmun diseas
success develop hla allel expans product
addit
clinical/regulatori failur delay scchn
higher expect competit exist new therapi
scchn cervic cancer
three program late-lin r/m scchn po regulatori approv first-lin r/m scchn
combin pembrolizumab po advanc cervic cancer po elect use
discount rate program given inher riski drug develop model risk-adjust us eu revenu
late-lin first-lin scchn contribut respect advanc cervic cancer add
npv npv analysi sum per share round
downsid risk pt rate could aris unexpect delay clinic develop product registr difficult
competit landscap hpv malign unfavor clinic outcom immuno-stat program
cambridg ma-bas clinical-stag biotechnolog compani
develop novel therapi oncolog autoimmun diseas cue
pipelin base proprietari immuno-stat platform innov
technolog design select activ suppress target subset t-
cell immuno-stat repres new class biolog therapeut could
deliv precis efficaci engin t-cell receptor tcr t-cell
therapi conveni effici off-the-shelf cytokin
product compani lead program select drive expans
hpv specif t-cell current evalu phase dose-
escal studi patient recurr metastat hpv-posit head
neck cancer second clinic candid design expand
specif t-cell could develop varieti heme/onc solid tumor
indic cue immuno-stat technolog pioneer dr steve almo
albert einstein colleg medicin attract two notabl research
collabor partnership merck enter research
collabor explor immuno-stat autoimmun diseas lg
chem in-licens asian right three immuno-stat product includ cue-
second product class dub neo-stat preclin develop
intend increas modular applic immuno-stat
initi coverag outperform rate
price target base assess commerci
potenti compani lead product hpv-driven cancer
believ could offer signific advantag exist standard
care hpv head neck cancer well cervic cancer believ
could achiev clinic proof-of-concept
publish signific bodi preclin evid demonstr
off-the-shelf inject biolog deliv potent anti-tumor
activ cancer cell express oncoprotein
exampl mous model hpv-driven cancer outperform
treatment antibodi see cue immuno-stat technolog
innov way dial specif cytokin therapi could
translat substanti improv safeti efficaci rel untarget
cytokin nektar bempegaldesleukin bempeg view cue-
technolog could offer level target t-cell activ could
previous achiev costli person tcr-t therapi
gilead believ develop partial de-
risk clinic track record tcr-t product demonstr
object respons hpv-driven cancer
unlik tcr-t cell therapi off-the-shelf biolog design
stimul endogen t-cell recogn hpv antigen
develop version optim patient european descent
version could introduc differ geographi depend
preval differ human leukocyt antigen hla serotypesfor exampl
lg chem focus version compat asian hla
mani way thought extrem well-deliv highli
precis applic therapi thu investor awar
substanti biopharma interest invest cytokine-bas therapi
bristol-my squibb partnership nektar develop bempeg
came up-front payment also acquir
armo bioscienc lead variant transact
recent sanofi recent acquir synthorx variant
base valuat success develop
squamou cell carcinoma head neck scchn initi
relapsed/refractori set subsequ label expans front-lin
set combin inhibitor also model cervic
cancer albeit higher risk adjust believ
increas address market opportun expand
addit hla serotyp beyond initi translat data
phase trial expect follow potenti proof-of-
concept expect could serv major catalyst sharehold
part npv methodolog summar exhibit model includ
contribut three program seri late-
line r/m scchn probabl success po regulatori
approv first-lin r/m scchn combin
pembrolizumab po regulatori approv
advanc cervic cancer po regulatori approv elect
use discount rate program given inher riski drug
develop project potenti fda approv scchn
advanc cervic cancer respect
sum-of-part valuat includ project cash posit per share
model risk-adjust us eu revenu late-lin first-
line scchn contribut respect
project valu advanc cervic cancer add npv
includ cash per share npv analysi sum per share
round detail market model scchn cervic cancer see
exhibit
potenti initi translat monotherapi data scchn part
potenti proof-of-concept efficaci result scchn part
potenti initi dose-expans portion scchn part
potenti initi combin cohort pembrolizumab scchn part
compani present oppenheim co estim
drug develop inher riski invest thesi depend
biopharma abil success develop manufactur commerci
therapi biotechnolog compani fail delay
inconclus clinic trial could exert downward pressur stock
compani may experi delay initi enrol complet
clinic trial result pivot trial may fail reproduc posit
result observ earlier trial acknowledg multipl compet
therapeut modal clinic treat advanc hpv-associ
malign includ target oncoprotein exampl
tcr-t cell therapi target alreadi demonstr activ hpv-
relat cancer could potenti set new efficaci bar clear
develop new therapeut class
previous evalu human yet establish clinic proof concept
novel therapeut unexpect safeti signal may emerg phase
dose escal addit cue product may abl demonstr
efficaci clinic despit potent activ observ rodent model
anim model may adequ account tumor resist mechan
limit efficaci immunotherapi clinic
thesi subject financ risk estim suffici
cash sustain oper earli includ multipl
dilut equiti rais model could sustain oper
compani potenti achiev sustain profit howev
compani may requir addit dilut financ achiev sustain
pipelin clinic program
introduct immuno-stat platform
new take cancer immunotherapi
leverag immun system attack tumor foundat immuno-
oncolog i/o treatment modal rapidli emerg becom one
five main pillar cancer therapyalong surgeri radiat
chemotherapi precis therapi immunotherapi roughli divid
two major world broadly-stimul agent checkpoint
antibodi cytokin therapi indiscrimin activ t-cell
highli specif person cell therapi includ car-t tcr-t
til product approach limit checkpoint
antibodi especi antibodi reshap treatment
landscap mani cancer agent inact varieti tumor type
off-target side effect limit clinic util hand cellular
therapi car-t tcr-t til effect direct t-cell
tumor targetsbut manufactur product remain rel
cumbersom expens time-consum process due uniqu
architectur immuno-stat coupl immunomodulatori cytokin
domain molecular zip code direct activ toward specif t-cell
popul believ could potenti bridg best world
immuno-stat modular multi-domain fusion protein design
select activ suppress endogen t-cell specif
mhc mount alongsid multipl secondari domain either
costimulatori inhibitori depend intend applic mani way
immuno-stat replic role antigen present cell apc
bodi specialist mount immun respons pathogen
exhibit immuno-stat replic function apc
cue lead product use well-character hpv antigen
mount mhc complex antigen display hpv-driven cancer
includ scchn cervic cancer illustr exhibit
contain two copi mhc complex four costimulatori
domain tether antibodi fc domain
due complex mhc/tcr bind would expect singl
immuno-stat product compat patient even tumor
uniformli express hpv across larg popul subtl variat
mhc/tcr bind interfac prevent format product complex
refer mhc-restrict antigen recognit result
differ immuno-stat must manufactur depend target
popul ensur compat reflect target market
incorpor class mhc estim compat
patient european descent immunol
exhibit architectur
importantli specif impart mhc-tcr interact
domain costimulatori domain case
provid second signal promot focus t-cell expans could allow
patient mount effect respons hpv tumor
cytokin therapi without safeti baggag
view one main advantag immuno-stat technolog
potenti allow target deliveri highli potent stimulatori cytokin
danger deliv system system administ
approv use select indic includ melanoma renal cell
carcinoma system activ receptor make drug extrem toxic
result limit therapeut window
importantli domain modifi point mutat
reduc affin receptor exampl introduct point
mutat reduc affin subunit
appear lower bind affin tcr-mhc interact requir
stabil product complex word bind
cooper depend specif inher tcr-mhc
complex preclin increas dose increas percentag
hpv t-cell bound nave t-cell cmv-
exhibit bind depend mhc-tcr interact
potenti differenti safeti profil lead
gener increas inflammatori cytokin product vitro shown
exhibit peripher blood cell healthi volunt stimul
increas concentr either hour
dose led appreci chang inflammatori cytokin product
stark contrast gener led sharp increas ifn- tnf-
level
exhibit trigger gener product inflammatori cytokin
domain also contain modif design improv
downstream impact singl point mutat abrog affin
decreas recal receptor
predominantli express regulatori t-cell well certain non-immun
cell includ endotheli cell activ wide believ
contribut poor therapeut window immunol
concomit increas regulatori cell diminish effector
respons off-target activ endotheli cell may caus vascular
leak syndrom common toxic associ recombin therapi
sever drug develop vy make safer effect via
receptor bias attract interest big pharma bristol
myers-squibb paid nektar up-front joint right bempeg
recent sanofi acquir synthorx opinion cue immuno-
stat platform provid mean deliv therapi unpreced
precis key advantag illustr exhibit
exhibit potenti advantag proleukin receptor-bias
immuno-stat vs adopt cellular therapi t-cell engag
adopt cellular therapi act emerg treatment modal
provid lifelin patient certain cancer exhaust
altern approach conceptu simpl patient treat live
immun cell expand high number ex vivo goal
elicit robust anti-tumor respons certain form act car-t
tcr-t leverag genet engin redirect cell target
other til reli tumor-specif cell alreadi present patient
approach shown promis certain indic
person autolog product expens ineffici
tcr-t form act patient-deriv t-cell genet
modifi express specif tcr target specif antigen therefor
close parallel immuno-stat therapi approach shown
activ certain solid tumor includ hpv-associ cancer synovi
sarcoma melanoma believ clonal tcr-t therapi potenti
vulner acquir resist sinc subtl chang target
antigen/mhc complex may render tcr-t ineffect polyclon product
hand may recogn multipl variant antigen/mhc complex
immuno-stat capac gener polyclon t-cell popul
specif given antigen exampl tcr analys perform two donor
pbmc stimul show expans t-cell
polyclon one donor polyclon repertoir recogn
target hpv antigen well novel truncat form hpv clin
immuno-stat design stimul expand
target subset endogen t-cell vivo therebi elimin need
lengthi ex vivo expans step parallel
immuno-stat t-cell engag bispecif antibodi neither requir ex
vivo t-cell expans note bispecif may disadvantag
provid cytokin support effect control
type t-cell bridg tumor target like bcma
immuno-stat distinct cancer vaccin
immuno-stat cancer vaccin although approach share
end goal induct adapt anti-tumor respons cancer vaccin
typic contain peptid mix cover target antigen inject
patient along adjuv effect vaccin peptid must
taken apc present t-cell goal stimul t-
cell activ expans particular mhc/antigen complex
unfortun process antigen present apc complex
ineffici vulner interfer sever step along process
view complex like contribut checker develop
record cancer vaccin far clinic immuno-stat effect cut
apc middle-man provid short-cut target effector t-cell
activ therefor may less suscept interfer
unfortun tumor sever known method dispos
sabotag function apc illustr exhibit exampl
tumor secret signal suppress apc activ even convert pro-
inflammatori apc pro-regulatori apc cut apc
equat believ immuno-stat could potenti overcom sever
core issu plagu develop cancer vaccin
exhibit tumor multipl mean impair apc function
take crack head neck
current evalu phase studi patient hpv
scchn rel rare larg incur cancer associ
scchn cervic sever rarer epitheli cancer ideal prove ground
immuno-stat platform activ express compon
hpv viru provid excel target immun system hpv
essenti compon malign transform constitut express
hpv cancer cell-bas therapi includ tcr-t target
antigen deliv encourag earli sign efficaci see
posit sign expect initi translat data
phase trial follow potenti clinic proof-of-concept
hpv play well-character role scchn pathogenesi
hpv infect commonli diagnos sexual transmit diseas
link cancer long-last infect certain hpv serotyp caus
cancer varieti tissu includ cervix oropharynx anu
rectum extent hpv caus cancer epitheli tissu
vari cancer type exampl hpv account head
neck cancer cervic cancer lancet oncol
epub feb certain prevent vaccin target
hpv includ merck gardasil shown effect reduc
risk develop hpv cancer recommend routin
vaccin adolesc
multipl serotyp hpv viru discov
culprit major hpv-associ cancer extens
character viral genom encod sever earli protein
late protein earli protein requir replic
transcript genom late protein necessari produc
viral capsid protein play distinct role promot oncogen
transform inhibit tumor suppressor protein prb
note hpv cancer tend better prognos hpv- cancer
tissu recent retrospect studi found head neck cancer
patient hpv diseas significantli extend overal surviv rel
hpv- diseas month vs month per clin oncol
suppl abstract improv prognosi like aris improv
immun surveil support evid tumor biopsi
show hpv cancer higher degre tumor infiltr
lymphocyt til believ improv immun explain
enhanc reactiv viral protein includ viral
deriv protein highli antigen front oncol
current treatment option scchn limit
head neck cancer aggress come five-year mortal
term head neck cancer describ heterogen mix tumor type
develop anatom region paranas sinus nasal caviti oral
caviti tongu salivari gland larynx pharynx earli detect
resect come favor prognosi patient recurr and/or
metastas diseas lower overal five-year surviv median
surviv month depend individu patient characterist
patient relaps and/or metastat diseas system therapi includ
checkpoint inhibitor chemotherapi and/or target therapi
cetuximab use clinic treatment algorithm depend prior
treatment patient comorbid tumor express statu
immun checkpoint inhibitor integr standard care
scchn pembrolizumab becam first-lin treatment metastat recurr
diseas set base trial
evalu pembrolizumab alon chemo vs standard extrem regimen
platinum-bas therapi cetuximab orr ident
pembrolizumab combin versu extrem overal surviv
improv combin arm mo month vs month
unfortun patient receiv system therapi ultim relaps
current consensu standard-of-car case patient
progress frontlin platinum-bas chemotherapi elig
immunotherapi antibodi often next line treatment
pembrolizumab monotherapi gener
orr respons last six month
respons rate durat respons similar regardless hpv statu
nivolumab demonstr compar object respons similarli
approv previous treat scchn
de-risk tcr-t til
nation cancer institut nci current investig
target tcr-t tcr-t out-licens kite pharma
gilead hand investig nci tcr-t dub kite-
deliv earli object evid efficaci three partial
respons seven evalu patient abstract
data cut respons last long nine month
occur patient vulvar oropharyng anal cancer patient
previous receiv treatment inhibitor gilead initi
phase trial
nci also activ explor tumor infiltr lymphocyt til
investig therapi scchn unlik tcr-t til polyclon mix
non-engin t-cell harvest directli tumor biopsi result
recent publish phase trial nci demonstr respons
rate amongst cervic cancer patient respons rate two
amongst non-cerv hpv cancer patient importantli hpv-reactiv
til correl respons mean patient whose til
includ and/or cell like respons clin
cancer separ iovanc develop
til product scchn preliminari data multicent phase
studi patient recurr and/or metastat scchn
includ three pr eight efficacy-evalu patient orr per
support strong preclin
work clinic would expect elicit focus
expans hpv t-cell vitro illustr exhibit
cultur healthi donor blood cell induc select expans
use adjuv detect flow cytometri
treatment induc select expans hpv t-cell clone
undetect frequenc baselin importantli induc non-
specif effector cell expans highlight select approach
increas concentr led dose-depend increas hpv
t-cell rel small chang t-cell
tame hpv cancer mous model
murin tumor model express oncoprotein
respond well treatment treatment murin analogu
led better control tumor extend overal surviv
combin inhibitor led synergist anti-tumor activ
extend surviv combination-tr mice re-challeng
tumor achiev control without intervent signifi
develop immunolog memori exhibit
exhibit extend surviv mous model
translat work mous studi show treatment led
hpv cell activ wherea treatment
combin result higher degre antigen-specif t-cell activ
shown anti-tumor activ reli t-cell lesser
develop path hpv scchn
current evalu phase trial
second line greater scchn per protocol
patient must previous receiv platinum-bas chemotherapi
offer checkpoint immunotherapi prior enrol patient receiv cue-
everi three week via iv infus open-label studi consist two
portion dose-escal phase part follow expans phase part
 addit object respons dose escal expans phase
also measur effect multipl biomark includ induct
hpv cell peripher blood chang til base
biopsi pre- post-treat anticip initi translat biomark
data addit compani plan evalu
combin therapi combin dose escal potenti
begin
competit landscap head neck
given high clinic unmet need multipl therapeut strategi
pursu treatment sschn summar exhibit scchn
tumor character immunosuppress tumor microenviron
drug develop focus prime recruit immun cell
tumor exampl roch develop engin moieti
activ effector t-cell nk-cell
simultan reduc treg activ help overcom intratumor
vector-bas dna- rna-bas also explor clinic
view adopt cell therapi demonstr
compel data rel investig approach previous
mention iovanc gener object respons three eight
treat subject on-going phase trial addit antigen-specif tcr-t
therapi also gener respons earli clinic trial gilead kite-
tcr-engin cell shown encourag initi respons
patient relapsed/refractori hpv solid tumor
pr observ three seven evalu patient anoth two
exhibit competit landscap m/r scchn
nsclc w/
interim data expect
odn agonist
w/ pembro anti-
combo result trend
prolong mo compar
cetuximab
hras-mut
mdor nr combo w/
combo w/ pembro mdor
interim updat expect
phase orr
orr pt
median four prior
pt object
respons pt prior
pt partial respons
patient prior
r/m scchn
orr patient
oppenheim co research biomedtrack
exhibit strategi treat scchn
wang h-c chan l-p cho s-f front oncol
market opportun head
neck cancer
model market opportun r/m scchn first-lin
therapi combin pembrolizumab well late-lin monotherapi
assum would initi approv relapsed/refractori
set follow label expans front line combin
pembrolizumab per seer cancer statist estim new
case death us year
estim would appropri approxim us eu
patient base preval allel
front-lin set estim roughli annual case
unresect requir system treatment assum peak penetr rate
use therapi cost per patient assum peak us
revenu eu assum lower treatment cost
per patient peak sale first-lin set
late-lin r/m scchn project hpv-posit hla-
elig patient us respect given high-
unmet need later-lin set assum higher peak penetr rate
use estim therapi cost us
eu respect model combin us/eu peak sale late-
exhibit market model r/m scchn
hpv r/m hnscc elig popul cost market size penetr treat hpv r/m hnscc elig popul cost market size penetr treat revenu revenu profit oper tax probability-of-success discount rate valu npv assum recurrent/metastat hnscc outperform
exhibit market model r/m scchn
hpv r/m hnscc elig popul cost market size penetr treat hpv r/m hnscc elig popul cost market size penetr treat revenu revenu profit oper tax probability-of-success discount rate valu npv assum recurrent/metastat hnscc w/ pembrolizumab biopharma
beyond scchn may advanc hpv-posit
malign includ advanc cervic cancer nearli case cervic
cancer attribut hpv infect us case
cervic cancer annual attribut hpv account
approxim half case avail hpv vaccin
decreas annual incid rate cervic cancer continu contribut
patient death per year us alon per seer statist
standard-of-car first-lin treatment metastat recurr cervic
cancer consist platinum-bas chemotherapi combin bevacizumab
anti-vegf antibodi approv combin chemotherapi
first-lin treatment improv median overal surviv random
phase trial chemotherapi play limit role second
late-lin set treatment gener associ low respons rate
surviv benefit checkpoint inhibitor includ
pembrolizumab demonstr favor clinic outcom advanc
cervic cancer pembrolizumab approv base phase
clinic trial women recurr
metastat cervic cancer whose tumor express score
studi gener orr respons last six month
establish proof-of-concept scchn on-going dose-
escal studi believ compani could initi separ cohort
advanc cervic cancer would also target
patient popul cervic cancer assum po
late-lin therapi recurr metastat cervic cancer summar
exhibit estim late-lin address cervic cancer
patient us anoth address patient eu assum
annual price us estim peak market opportun
cervic cancer us peak market
penetr similarli eu assum annual price
peak sale market model advanc cervic cancer shown
exhibit market model cervic cancer
hpv r/m cervic cancer elig cost market size penetr treat hpv r/m cervic cancer elig cost market size penetr treat revenu revenu profit oper tax probability-of-success discount rate valu npv assum advanc cervic cancer biopharma
notabl gem earli stage pipelin
addit target hpv antigen hpv-posit cancer cue
early-stag pipelin focus non-vir antigen exampl
util mhc lead peptid deriv wilm tumor protein
non-vir oncofet antigen overexpress variou solid
tumor hematolog malign compani plan conduct preclin
studi collabor lg chem manag also
express interest target kra specif use
architectur exhibit given earli clinic stage
develop current includ kras-target
immuno-stat valuat similarli present includ
potenti hla allel expans product model
immuno-stat platform stimulatori cytokin domain readili
interchang inhibitori molecul dial t-cell activ
could use treat autoimmun disord product basi
cue collabor merck
summari key patent expir date relev cue core technolog
platform lead program shown exhibit
patent immuno-stat platform screen
viratop variant
end report cash posit
estim suffici resourc sustain oper earli
model dilut rais could sustain compani
profit growth estim project net loss
per share respect
expect see increas cash burn associ increas reflect
compani clinic expens oncology-bas program
clinic pipelin consist sever early-stag candid
project meaning revenu estim non risk-
adjust peak us sale r/m scchn
r/m scchn r/m cervic cancer project could
launch r/m scchn gener first-year revenu
similarli model commerci launch r/m cervic cancer
project first-year sale
estim expens sg expens
expect total oper expens per year
assum cog believ line
biolog therapi monoclon antibodi
presid chief scientif offic
vice presid financ
passeri ceo prior join mr
passeri serv presid chief execut offic well vice
chairman board curi inc prior curi senior vice
presid role corpor develop strateg plan
genelog prior work genelog mr passeri serv director
technolog manag boehring mannheim mr passeri receiv
nation law center georg washington univers sc
imperi colleg scienc technolog medicin
univers london biolog northeastern univers
dr anish suri ph presid chief scientif offic
anish suri chief scientif offic dr suri
immunologist extens experi basic translat research
focus immuno-oncolog autoimmun disord transplant reject
inflamm prior held role janssen
strateg immunosci initi prior janssen respons
provid strateg guidanc immuno-oncolog immunolog drug
discoveri program bristol-my squibb pharmaceut research institut
prior work pharmaceut industri dr suri assist professor
patholog immunolog washington univers school medicin
receiv ph immunolog washington univers st loui
kerri-ann millar vice presid financ princip account
kerri-ann millar serv vice presid financ princip
account financ offic join ms millar serv
corpor control inc biopharmaceut
compani focus develop local therapi treatment
patient osteoarthr develop financ function
newli public compani support commerci first approv drug
prior serv financ specialist curi inc
biotechnolog compani focus develop oncolog treatment
prior curi ms millar spent ten year audit financ function
sever invest bank boston area four year
pricewaterhousecoop earn account financ
boston univers certifi public account
kenneth pienta act chief medic offic dr pienta
also donald coffey professor urolog well professor
oncolog pharmacolog molecular scienc chemic
biomolecular engin john hopkin univers current
director research bradi urolog institut also serv co-
director john hopkin individu health initi dr pienta
author peer-review articl two-tim american
 human biolog john hopkin univers
john hopkin univers school medicin board certifi oncolog
sec file oppenheim co research
figur thousand except per share sale collabor good sold sell gener administr research develop oper loss expens loss unreal gain loss available-for-sal incom loss per share share outstand co mark breidenbach outperform
sec file oppenheim co research
figur thousand except per share cash secur short expens current total current leas cash long long term current liabil account contract liabil current leas liablil current current contract liabil net current leas liabliti net current stockhold equiti prefer stockcommon paid-in comprehens stockhold equiti liabil stockhold co mark breidenbach biopharma
stock price compani mention report februari
